tislelizumab
beigene,novartis
$bgne $nvs beigene announces late-breaking data at esmo gi showing overall survival benefit for tislelizumab plus chemotherapy in first-line advanced or metastatic esophageal squamous cell carcinoma - 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities